
Feds launch crackdown on kratom byproduct
Why it matters: The compound, 7-hydroxymitragynine, is commonly sold online and in smoke shops and has been found in dangerous concentrations in tablets, gummies and drink mixes.
Driving the news: FDA and Drug Enforcement Administration officials said Tuesday they are taking steps to schedule the compound as a controlled substance and released a report on its risks to educate the medical community, schools and parents.
The FDA has also issued warning letters to seven companies for illegal marketing products containing 7-OH. The products advertise the compound as an added ingredient, or being included at enhanced levels.
Distributors claim products with the substance act as "unapproved new drugs with unproven claims such as relieving pain and managing anxiety," the agency said.
HHS Secretary Robert F. Kennedy Jr. referenced his own history with heroin addiction at a Tuesday event promoting the crackdown, during which he described the importance of cracking down on the easily available synthetic opioid.
"I became an addict because [heroin] was so available, but I had to go to the South Bronx or the Lower East Side. But now you can go to any gas station," Kennedy said.
"They're putting them around schools, putting them in our poorest neighborhoods and now they are putting them in every gas station," he continued. "They're marketing them to children, they're gummy bears, they're bright colors, they're candy flavored. This is really a sinister, sinister industry."
Officials said they are not targeting the herbal supplement kratom but the byproduct.
Research has shown 7-OH can be 13 times more potent than morphine, FDA Commissioner Marty Makary said.
"7-OH is not just 'like' an opioid ... it is an opioid," Makary said. "And yet it is sold in vape stores, in smoke shops, in convenience stores, in gas stations that are popping up around the United States. And no one knows what it is."
He declined to weigh in on the safety of kratom products, which have intoxicating effects and have been the target of new and proposed restrictions in Colorado and Louisiana.
"Lets not let another wave of the opioid epidemic catch us blind-sided again," Makary said.
The move was cheered by some kratom proponents who say the agency's action differentiates what's illegal from legitimate products.
"For too long, the conversation around kratom has been polluted by bad actors and misinformation," said Paula Brown, director of Natural Health & Food Products Research at the British Columbia Institute of Technology.
"FDA's data now supports what pharmacognosists have known for years: kratom is not a narcotic, and 7-OH is not a natural constituent of the plant. Differentiating them is both scientifically necessary and ethically urgent."
The other side: "Over half a billion doses of 7-OH have been used without a single confirmed death. That's not a threat to public safety—that's a success story," said Jeff Smith, National Policy Director of the Holistic Alternative Recovery Trust (HART). "This compound deserves to be regulated like any responsible product."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
an hour ago
- Business Upturn
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007
By GlobeNewswire Published on August 4, 2025, 23:31 IST PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18, including a placebo-controlled arm. A parallel study presented to FDA and to be conducted by Immuthera has been received favorably, may include Polish patients in the U.S. Statistical analysis, and could be treated as pivotal. The project has received an $11.3 million non-dilutive grant from the Polish Medical Research Agency. PolTREG is developing Multi-edited, Allogeneic CAR-Tregulatory cell therapies which can be used to treat patients diagnosed with T1D (Stage 3), which, in combination with PTG-007 in Stage 1 and Stage 2, will provide clinical solutions for patients across all Stages of T1D. 4 August 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a pioneer in cell therapies for autoimmune diseases, and its U.S. subsidiary Immuthera, announced that they have administered the first dose of PTG-007 to a patient in their Phase II clinical trial for pre-symptomatic type 1 diabetes. The trial, called 'Pre-Treg' will enroll up to 150 genetically high-risk children and adolescents (aged 3–18) who have not yet developed clinical symptoms of the disease. If successful, PolTREG aims to develop and register the world's first therapy to prevent the onset of type 1 diabetes symptoms. The company has proposed a parallel study to Pre-Treg to the U.S. Food and Drug Administration (FDA) in a recent Pre-IND meeting. The FDA's response was that the U.S. Trial could potentially be registrational. Further, patients enrolled in Poland at Stage 1 of the disease may, upon completion of enrollment, be included in the U.S. statistical analysis of the study. 'Long-term data from our clinical program of PTG-007 in symptomatic type 1 diabetes confirm both the safety and efficacy of the therapy. Modern medicine is increasingly focusing on interventions applied earlier or even before the first clinical symptoms appear. Our therapy fits perfectly into this paradigm. By administering it at the earliest stage of disease development, we anticipate highly promising outcomes—possibly even halting disease progression before clinical symptoms emerge. If the trial confirms the therapy's efficacy, we have the opportunity to develop and register the world's first drug to prevent the clinical onset of type 1 diabetes. We believe this therapy holds significant market and partnership potential' – said Prof. Piotr Trzonkowski, CEO and Co-Founder of PolTREG S.A. The Phase II study will include 150 participants in a randomized, placebo-controlled design. Recruitment is ongoing at three academic centers in Poland, with six additional clinical hospitals set to begin enrollment shortly. PolTREG has been awarded a non-dilutive grant of PLN 31.7 million (approx. $11.3 million) from the Polish Medical Research Agency to support the execution of this Phase II trial. PreTreg is one of PolTREG's flagship programs. In type 1 diabetes, the autoimmune destruction of insulin-producing pancreatic islets underscores the importance of early intervention. In the pre-symptomatic phase, a sufficient number of islets remain to maintain normal glucose regulation, and the autoimmune process is still limited and more readily controllable. Preventive therapy at this stage could halt the autoimmune attack, leaving patients genetically predisposed but clinically healthy for life. Upon successful completion of this trial and confirmation of safety and efficacy, PolTREG could establish the first approved drug to prevent symptomatic type 1 diabetes. Type 1 diabetes progresses through three stages. Stages 1 and 2 is considered presymptomatic and occurs in young children, typically 3 years old or older. Because these patients are not yet sick, safety is the highest priority. PTG-007's 12 year safety data makes it an ideal treatment for this age group and this stage of disease. Diagnosis of Type 1 Diabetes occurs in Stage 3 when symptoms occur which can lead to potentially life threatening complications such as diabetic ketoacidocis, heart and blood vessel disease, nerve damage, eye damage, kidney disease, and foot damage. These patients are typically older and require supplemental insulin. Due to the complications in Stage 3, more aggressive treatments are warranted. PolTREG and Immuthera are developing Tregulatory cell therapies that have clinically derived edits to improve function, modifications to make them 'off-the-shelf' (allogeneic), and a Chimeric Antigen Receptor to improve targeting of the disease causing cells that drive the autoimmune response. Taken together, PolTREG and Immuthera have a pipeline of Tregulatory cell therapies that will cover the full spectrum of presymptomatic and symptomatic Type 1 Diabetes. PolTREG is also expanding its U.S. presence. In mid-June, the company established its wholly owned U.S. subsidiary, Immuthera, registered as a Delaware C Corporation. In recent weeks, prominent experts in diabetes and neuroimmunology—Prof. Jay Skyler, Prof. Desmond Schatz, and Prof. Lawrence Steinman—joined the company's Scientific Advisory Board. In late July, PolTREG received the formal outcome of its pre-IND meeting with the FDA and is now preparing its IND submission. The company has partnered with Noble Capital Markets, Inc. and Kinexum Services LLC to support its U.S. regulatory strategy, and is collaborating with Swiss-based Antion Biosciences to develop next-generation allogeneic Treg therapies. About PolTREG: PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies. About Immuthera: Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG's Research and Development capabilities and asset pipeline along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. For further information please contact: PolTREG Piotr TrzonkowskiChief Executive Officer [email protected] +48 512 532 401 Important information The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements'. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes', 'estimates,' 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'continue', 'ongoing', 'potential', 'predict', 'project', 'target', 'seek' or 'should', and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.


The Hill
an hour ago
- The Hill
FDA upgrades nationwide butter recall alert to a higher level
(NewsNation) — The Food and Drug Administration (FDA) has escalated a recent nationwide recall of 64,800 pounds of butter to a higher risk level. The risk classification for one of Bunge North America Inc.'s butter products was raised to Class II, which is the second highest warning level, due to an ingredient not listed on the food packaging: milk. Milk is one of nine major food allergens, according to U.S. food safety laws, along with eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans and sesame seeds. According to the FDA, manufacturers are required to declare the name of the food source of a major food allergen. The FDA did not say whether anyone had been adversely affected in connection with the recall. In a July 14 report, the FDA said more than 1,800 cases of the NH European Style Butter Blend were distributed at 12 centers across the U.S. and one in the Dominican Republic. The lot code number for the butter is 5064036503. According to the FDA's website, a Class II recall indicates 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.' Nexstar's NewsNation has reached out to Bunge North America for comment. Bunge North America Inc., based in Chesterfield, Missouri, is an agribusiness and food ingredient company that also produces corn, wheat, rice, soybeans and feed peas, among other items.


Fox News
an hour ago
- Fox News
WATCH LIVE: Kennedy, Rollins make announcement about Trump's 'Make America Healthy Again' effort
HHS Secretary Robert F. Kennedy Jr., USDA Secretary Brooke Rollins and FDA Commissioner Marty Makary are joined by Iowa Gov. Kim Reynolds and West Virginia Gov. Patrick Morrisey for the announcement.